Assessing adverse events and clinical outcomes in patients with multiple sclerosis on Rituximab versus biosimilar

In a real-world practice setting of Kaiser Permanente Northern California (KPNC), what are the effects of switching from Rituxan to Truxima as primary therapy for patients with multiple sclerosis (MS). Aims are to determine and compare the rates of adverse events for MS patients in KPNC on Rituxan versus Truxima during the study period and to assess and compare the rates of MS flares for MS patients in KPNC on Rituxan versus Truxima during the study period.

0